Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated profit ...
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...
No-moat Dr. Reddy’s reported mixed second-quarter earnings ... Reddy’s closed the nicotine therapy portfolio acquisition from Haleon. Management noted that business integration is underway ...
Dr Reddy's Labs reports 9.5 percent fall in consolidated net profit after tax to Rs 1342 crore in Q2
Indian generic drugmaker Dr Reddy's Laboratories recorded a 9.5 percent decline in its consolidated net profit after tax to ...
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories ...
Dr. Reddy's Laboratories Limited ( NYSE: RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez ...
HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter ... Nicotinell, from Haleon in June. During the quarter, the company had charged off a debt tax ...
The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.
Dr. Reddy’s Laboratories’ (DRL ... Acquisition of NRT business from Haleon, consolidation of Sanofi’s vaccine portfolio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback